Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 5/20 | 0.42 |
| ▸ | CCR5 | P51681 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029963 | 1.00 | RORC (0.43) | RORCMC4RCCR5SLC6A4CHRM2 | |
| SCHEMBL3030463 | 0.92 | RORC (0.43) | RORCMC4RCCR5CHRM2CHRM1 | |
| SCHEMBL3024721 | 0.89 | MC4R (0.41) | RORCMC4RCCR5SLC6A4CHRM2 | |
| SCHEMBL3024717 | 0.89 | MC4R (0.41) | RORCMC4RCCR5SLC6A4CHRM2 | |
| SCHEMBL3029751 | 0.81 | RORC (0.41) | RORCMC4RCCR5CHRM2CHRM1 | |
| SCHEMBL3029693 | 0.81 | RORC (0.46) | RORCMC4RCCR5 | |
| SCHEMBL3026998 | 0.79 | TACR1 (0.40) | RORCMC4RCCR5CHRM2CHRM1 | |
| SCHEMBL3027003 | 0.79 | TACR1 (0.40) | RORCMC4RCCR5CHRM2CHRM1 | |
| SCHEMBL3025274 | 0.79 | TACR1 (0.41) | RORCMC4RCCR5SLC6A4CHRM4 | |
| SCHEMBL3025273 | 0.79 | TACR1 (0.41) | RORCMC4RCCR5SLC6A4CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398768-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 1018/4885MC4R 109/4885CCR5 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.